Research and Development

Funding from a consortium worth £875,000 pounds has helped kick start a new dementia drug research program at the University …

Astellas Pharma has received approval from the Ministry of Health, Labour and Welfare in Japan for a supplemental new drug …

Shares at troubled Valeant plummeted some 20% Monday after the company said it was under investigation by the Securities and …

AstraZeneca and its global biologics research and development arm, MedImmune, have announced a setback in the result of their Phase …

French biotech GenSight has begun enrolling patients for two parallel pivotal Phase III trials with its lead candidate GS010, a …

Eli Lilly’s Taltz (ixekizumab) has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for …

Roche has reported contradictory results from two identical Phase III studies of lebrikizumab in severe asthma, with one showing the …

UCB Pharma’s Briviact (brivaracetam) has been authorised as an add-on treatment for partial onset seizures (POS), with or without secondary …

Strong Phase III results have seen the US FDA approve Roche’s Gazyva (obinutuzumab) plus Levact (bendamustine) chemotherapy followed by Gazyva …

On Rare Disease Day 2016, UK charity Findacure says existing drugs may hold the key to new treatments and repurposing …

Boehringer Ingelheim has launched a collaborative initiative aimed at raising awareness and understanding of the rare lung disease Idiopathic Pulmonary …

Novartis’ cancer drug Afinitor (everolimus) has been granted FDA approval in a new indication: for the treatment of adult patients …

Eisai has aimed strong criticism at NHS England for its approval of reforms to the Cancer Drugs Fund, calling the …

The Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the EMA, has adopted a positive opinion …

Boehringer Ingelheim has revealed pooled analysis data from three trials, showing that its drug OFEV significantly reduces the risk of …